Although other mutations may predate the acquisition of the JAK2 V617F mutation, the latter is sufficient to drive the disease phenotype observed in BCR-ABL-negative myeloproliferative neoplasms (MPNs). One of the consequences of JAK2 V617F is genetic instability that could explain JAK2 V617F -mediated MPN progression and heterogeneity. Here, we show that JAK2 V617F induces the accumulation of reactive oxygen species (ROS) in the hematopoietic stem cell compartment of a knock-in (KI) mouse model and in patients with JAK2 V617F MPNs. JAK2 V617F -dependent ROS elevation was partly mediated by an AKT-induced decrease in catalase expression and was accompanied by an increased number of 8-oxo-guanines and DNA double-strand breaks (DSBs). Moreover, there was evidence for a mitotic recombination event in mice resulting in loss of heterozygosity of Jak2 V617F . Mice engrafted with 30% of Jak2 V617F KI bone marrow (BM) cells developed a polycythemia vera-like disorder. Treatment with the anti-oxidant N-acetylcysteine (NAC) substantially restored blood parameters and reduced damages to DNA. Furthermore, NAC induced a marked decrease in splenomegaly with reduction in the frequency of the Jak2 V617F -positive hematopoietic progenitors in BM and spleen. Altogether, overproduction of ROS is a mediator of JAK2 V617F -induced DNA damages that promote disease progression. Targeting ROS accumulation might prevent the development of JAK2 V617F MPNs.
Although other mutations may predate the acquisition of the JAK2 V617F mutation, the latter is sufficient to drive the disease phenotype observed in BCR-ABL-negative myeloproliferative neoplasms (MPNs). One of the consequences of JAK2 V617F is genetic instability that could explain JAK2 V617F -mediated MPN progression and heterogeneity. Here, we show that JAK2 V617F induces the accumulation of reactive oxygen species (ROS) in the hematopoietic stem cell compartment of a knock-in (KI) mouse model and in patients with JAK2 V617F MPNs. JAK2 V617F -dependent ROS elevation was partly mediated by an AKT-induced decrease in catalase expression and was accompanied by an increased number of 8-oxo-guanines and DNA double-strand breaks (DSBs). Moreover, there was evidence for a mitotic recombination event in mice resulting in loss of heterozygosity of Jak2 V617F . Mice engrafted with 30% of Jak2 V617F KI bone marrow (BM) cells developed a polycythemia vera-like disorder. Treatment with the anti-oxidant N-acetylcysteine (NAC) substantially restored blood parameters and reduced damages to DNA. Furthermore, NAC induced a marked decrease in splenomegaly with reduction in the frequency of the Jak2 V617F -positive hematopoietic progenitors in BM and spleen. Altogether, overproduction of ROS is a mediator of JAK2 V617F -induced DNA damages that promote disease progression. Targeting ROS accumulation might prevent the development of JAK2 V617F MPNs.
INTRODUCTION
Myeloproliferative neoplasms (MPNs) are acquired clonal disorders of the hematopoietic stem cell (HSC) characterized by the hyperplasia of one or several myeloid lineages. A gain-of-function mutation in the gene encoding the JAK2 tyrosine kinase (JAK2
V617F
) is as a key molecular event in most of the patients suffering from Polycythemia vera (PV) and approximately half of those with essential thrombocythemia and primary myelofibrosis. [1] [2] [3] [4] JAK2 is essential in the downstream signaling of several cytokine receptors such as the erythropoietin receptor (EPO-R). JAK2 V617F mutant kinase transforms hematopoietic cells through cytokine hypersensitivity and cytokine-independent activation of the signal transducers and activators of transcription, the phosphatidylinositol 3 kinase (PI3K)/AKT and the mitogen-activated protein kinase pathways.
The role of JAK2 V617F in driving the phenotype of MPNs has been confirmed in various mouse models including knock-in (KI) mouse models, in which Jak2 V617F is being expressed under the control of the endogenous Jak2 promoter. [5] [6] [7] [8] [9] In patients, JAK2 V617F is duplicated by mitotic recombination in the majority of PVs leading to a loss of heterozygosity. Multiple evidences suggest that the intensity of JAK2 V617F signaling may explain how a single mutation could give rise to several phenotypically different disorders. 5, [10] [11] [12] Several additional mutations, most of them affecting genes involved in epigenetic regulation (for example, TET2, ASXL1, EZH2, IDH1, DNMT3A) and RNA splicing (for example, SRSF2) have been identified in MPNs. [13] [14] [15] [16] These mutations can predate JAK2 V617F or accumulate on a JAK2 V617F background. They may cooperate with JAK2 V617F to favor clonal dominance, to modify disease phenotype or to promote leukemic transformation.
Like the oncogenic BCR-ABL tyrosine kinase associated with chronic myeloid leukemia, JAK2
V617F was shown to stimulate the production of intracellular reactive oxygen species (ROS) in hematopoietic cell lines. [17] [18] [19] We have shown that JAK2 V617F generates genetic instability through deregulation of homologous recombination of DNA repair mechanisms leading to JAK2 V617F loss of heterozygosity and increased mutagenesis. 20 As oxidative stress is known to damage nucleic acids, 17, 21 we investigated the contribution of ROS to JAK2 V617F -driven pathology in Jak2 V617F KI mice. We show that ROS have a central role in the accumulation of DNA damages in HSCs, as well as in the development of the myeloproliferative disorder. This elevation in ROS level was in part due to the downregulation of catalase. We also bring the proof-of-concept that targeting ROS prevents disease progression.
MATERIALS AND METHODS

Jak2
V617F KI mouse model
To generate the KI mice, conditional flexed JAK2 (JAK2 FLEX/ þ ) KI mice were crossed with vav-Cre transgenic mice expressing the recombinase Cre. In the Cre-recombined JAK2 V617F/WT progeny, endogenous heterozygous expression of the Jak2 V617F gene is mainly restricted to the hematopoietic system from the fetal stage. These Jak2 V617F KI mice share most features with our previously described constitutive Jak2 V617F KI mice.
6,22 1 Bone marrow (BM) transplantation and N-acetylcysteine treatment All procedures were approved by the Institut Gustave Roussy ethics committee (protocol 2012_061). We grafted 1 Â 10 6 BM cells from 5-6-week-old Jak2 V617F KI or Jak2 WT littermate mice with 2 Â 10 6 competitor BM cells from wild-type (WT) mice into 6-week-old C57BL/6 lethally irradiated recipient mice. After 2 weeks, the treatment group received 1 mg/ml NAC (Sigma Aldrich, Saint Quentin Fallavier, France), in drinking water while the control group received water acidified at pH 2.5. Eleven weeks after transplantation, mice were injected intraperitoneally (i.p.) with NAC (150 mg/kg/day) or acidified water for 3 weeks before killing. 23, 24 Analysis of mice Hematocrit, red blood cell, platelet and white blood cells counts were measured using an automated counter (MS9, Schloessing Melet, Cergy Pontoise, France) on blood collected from the retro-orbital plexus in citrated tubes. For histology, spleen sections were fixed in formaldehyde and stained with hematoxylin/eosin/safran. Progenitor cell studies were carried out in methylcellulose media (MethoCult 32/34, Stemcell Technologies, Grenoble, France) without (endogenous erythroid colony) or with added EPO alone (CFU-E) or with IL-3, IL-6, TPO, SCF and EPO (burstforming unit-erythroid (BFU-E) and granulocyte/macrophage (CFU-GM)). Cultures were scored in duplicate at day 2 (CFU-E) or day 7 (BFU-E and CFU-GM).
Flow cytometric sorting and analysis
Cell suspensions from mouse BM and spleen were collected and stained with allophycocyanin-conjugated lineage (Lin) antibodies, including anti-CD3, B220, Gr-1, Mac-1, Ter119 and CD41 rat anti-mouse antibodies. For sorting or analysis of Lin
À cells were stained with antibodies against mouse Sca-1 (phycoerythrin-Cyanine 7, PE-Cy7) and c-Kit (peridin chlorophyll proteincyanine 5.5, PerCP-Cy5.5). The Sca-1-negative portion of the LSK stain was subdivided into the common myeloid progenitors (CD34 þ CD16/32 À ) and the megakaryocyte-erythroid progenitors (CD34 À CD16/32 À ) using antimouse CD34-PE and CD16/32-allophycocyanin-Cy7 antibodies. All antibodies were from eBiosciences (Paris, France). Data acquisition and analysis was conducted using a LSR-II flow cytometer and the FACS DiVA software (Becton Dickinson, Mountain View, CA, USA). Hematopoietic progenitor cells were sorted with a FACS MoFlo (Beckman Coulter, Roissy CDG, France).
Patient cells
MPN was diagnosed according to the WHO criteria. 25 Only JAK2 V617F -positive patients were selected after analyses of their mutational status using fluorescent competitive probes for quantitative real-time PCR as reported previously. 2, 4 Control peripheral blood samples were collected from patients undergoing leukapheresis or hemochromatosis. The study was approved by the Local Research Ethics Committee from the Hô tel-Dieu (Paris, France) and IGR (Villejuif, France) hospitals. Informed consent was obtained from each patient in accordance with the Declaration of Helsinki. Peripheral blood from controls (n ¼ 14) and JAK2
V617F
-positive MPN patients (n ¼ 9) was collected in sterile citrated tubes. Mononuclear cells were separated over a ficoll density gradient and CD34 þ cells were purified by a double-positive magnetic cell sorting system (AutoMACS, Miltenyi Biotec, Paris, France), according to the manufacturer's recommendations. Alternatively, CD34
þ cells were cultured in IMDM (Invitrogen, Life Technologies, Saint Aubin, France) with penicillin/streptomycin/glutamine, alpha-thioglycerol, bovine serum albumin, a mixture of sonicated lipids and insulin-transferrin, in the presence of recombinant human cytokines (25 ng/ml SCF, 100 U/ml IL-3 and 1 U/ml EPO) for 7 days.
Ba/F3 cell lines
The murine pro-B Ba/F3 cells stably expressing the human receptor of EPO (Ba/F3-EPO-R) and either human JAK2
WT or JAK2 V617F were grown in DMEM (Invitrogen) supplemented with 10% fetal bovine serum (Stemcell Technologies) in presence of 1 U/ml EPO. Treatment with AKTi (10 mM), LY294002 (10 mM) and AZD1480 (1 mM) (Euromedex, Souffelweyersheim, France) were performed in presence of 0.1 U/ml EPO.
Analysis of ROS levels
We used the redox-sensitive fluorochrome 5-(and-6)-chloromethyl-2 0 ,7 0 -dichlorodihydrofluorescein diacetate dye (Invitrogen) to measure intracellular ROS levels by flow cytometry. Stained Lin À and LSK cell subpopulations were loaded with 2 mM 5-(and-6)-chloromethyl-2 0 ,7 0 -dichlorodihydrofluorescein diacetate for 20 min at 37 1C before analysis by flow cytometry. Alternatively we used 25 mM dihydro-ethidium for 20 min at 37 1C (Invitrogen).
Dot blot 8-oxo-G
Genomic DNA was extracted from Lin À and BM mouse cells using the QIAamp DNA Mini Kit (Qiagen, Courtaboeuf, France). DNA (150, 200 and 500 ng) was vacuum dot-blotted onto a positively charged nylon membrane and immobilized by UV cross-linking. DNA was denaturated by incubating in 0.5 M NaOH and 1.5 M NaCl for 30 min at room temperature and the membrane was neutralized with 0.5 M Tris-HCl, pH 7.5 and 1.5 M NaCl for 30 min at room temperature. Oxidative DNA damage was detected utilizing an antibody directed against 8-oxo-G (Millipore, Molsheim, France). 
Determination of 8-oxo-G foci
Determination of g-H2AX foci
Cytospin slides were fixed in absolute methanol for 15 min at À 20 1C and rinsed in ice-cold acetone. After blocking for 30 min with 2% bovine serum albumin in PBS containing 0.1% Tween-20 slides were stained for 1 h at 37 1C with the mouse anti-phospho-H2AX (Ser139) antibody (1/200) (Upstate Biotechnology, Millipore). Slides were incubated with anti-mouse IgG-Alexa 488-conjugated secondary antibody (1/400) and stained with DAPI for microscopic examination. More than 100 cells were counted in three independent mice.
Quantitative PCR CD34
þ patient cells, LSK and Lin À mouse RNAs were extracted using the Qiagen RNeasy Micro or Mini Kit. Reverse transcription was carried out using random hexamers (Roche Diagnostics, Meylan, France) and reverse transcriptase (Invitrogen). For RNAs isolated from LSK cells, complementary DNAs were prepared with the SuperScript VILO cDNA Synthesis Kit (Invitrogen). Quantitative real-time PCR was performed using SYBR-Green (Applied Biosystems, Life Technologies, Saint-Aubin, France) and the Mx3000P Real-Time PCR system (Stratagene, Agilent Technologies, Massy, France). Expression of catalase was assessed and reported to the levels of cyclophilin A or 2-microglobin housekeeping genes.
Western blotting BM or Ba/F3-EPO-R cells were lysed in a buffer containing 20 mM Tris-HCl, pH 7.4, 100 mM NaCl, 1 mM EDTA, 1% Triton and 1 Â protease inhibitor mixture (Roche Diagnostics). Cleared lysate was mixed with Laemmli buffer and boiled for 5 min. Samples were resolved by electrophoresis on a 10% SDS-polyacrylamide gel and transferred to nitrocellulose membrane (Thermo Scientific, Evry, France). Membranes were blocked with 5% bovine serum albumin in Tris-buffered saline solution (Euromedex), with 0.1% Tween-20, washed and incubated with primary antibodies overnight at 4 1C. Monoclonal antibodies were used at a concentration of 1 mg/ml and polyclonal antibodies at a 1:1000 dilution. Horseradish peroxidaseconjugated goat anti-mouse and anti-rabbit antibodies (Jackson ImmunoResearch, Immunotech, Marseille, France) were added at 1:8 000 dilution for 1 h at room temperature. Proteins were visualized using Immobilon Western Chemiluminescent HPR Substrate system (Millipore).
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Statistical analysis
Results are presented as mean±s.e.m. Data were analyzed with the two-tailed Student's t-Test. *Po0.05; **Po0.01 and ***Po0.001.
RESULTS
Jak2
V617F KI mouse PV-like disorder is associated with increased ROS production, oxidative DNA damages and subsequent DNA DSBs The Jak2 V617F KI mice develop a severe PV-like disease, characterized by elevated hematocrit, platelet and white blood cell counts at 3 months of age (Figure 1a) . Using 2 0 ,7 0 -dichlorodihydrofluorescein diacetate staining, we detected a significant accumulation of ROS in both the immature hematopoietic Lineage À (Lin À ) cells and the HSC-enriched LSK cell fraction isolated from BM of the 3-month-old KI mice compared with WT control littermate mice (Figure 1b) . When ROS levels were compared in LSK, common myeloid progenitors and megakaryocyte-erythroid progenitors, we found higher amounts in the more immature progenitors (LSK and common myeloid progenitors) than in megakaryocyteerythroid progenitors suggesting that ROS accumulation occurs before commitment in KI mice. ROS react with nucleic acids, proteins and lipids causing oxidative damages. We evaluated the extent of oxidative DNA damages in response to increased ROS levels in KI mice. The intensity of 8-oxo-G lesions in DNA was measured in sorted Lin À by immunofluorescence ( Figure 1c ) and in total BM and Lin À cells by dot blot (Figure 1d ). There was a significant increase in 8-oxo-G levels in KI animal compared with WT littermate cells. The LSK cell compartment represents B0.1% of total BM cells, thus we did not purify enough DNA from this subset to run the dot blot assay. As DSBs can be linked to unsuccessful post-replicative repairs of the highly mutagenic 8-oxo-G DNA damages, we determined the amount of DSBs in Lin À and LSK cells sorted from KI and WT mouse BMs. Histone H2AX is phosphorylated and forms foci at sites of DSBs.
Phosphorylated H2AX (called g-H2AX) foci were detected by immunofluorescence and numbered and showed a marked increase in cells from KI mice (Figure 1e ). These results suggested that Jak2 V617F -induced ROS accumulation in vivo in KI mouse cells may be linked to increased oxidative damage to DNA leading to DSBs or DNA replication stress. 26 Treatment of KI mice with the anti-oxidant N-acetyl-L-cysteine alleviates PV-like disease phenotype To test for a possible contribution of increased ROS levels and DSBs to the disease phenotype of KI mice, we proceeded to a long-term treatment in vivo of sick animals with the anti-oxidant NAC. Although human MPNs are clonal disorders in which progenitors are a mixture of normal cells with heterozygous and homozygous clones, 10 all HSCs are Jak2 V617F -positive in our KI mouse model. To better mimic the human pathology and appreciate whether ROS elevation may allow Jak2 V617F -positive cells to out compete normal Jak2
WT cells and thus cause disease progression, we transplanted a mixture of donor KI and WT BM cells in lethally irradiated mice. We engrafted 3 Â 10 6 BM cells from 6-week-old mice containing either 30% KI cells or 30% WT littermate cells as controls in competition with 70% of WT cells in 6-week-old recipient mice (Figure 2a) , and we treated these animals (KI CT and WT CT , 'CT' for competitive transplantation) with either NAC or vehicle (VEH, H 2 O/pH 2.5). Treatment was started 2 weeks after engraftment. NAC or VEH was administered orally and combined with daily i.p. injections at week 11 after transplantation for 3 more weeks before killing and analysis. Blood parameters were monitored every 2 weeks as a readout to follow progression of the disease. All KI CT mice, engrafted with Jak2 V617F -positive cells, displayed high numbers of red blood cells, platelets and white blood cells compared with WT CT mice, up to 14 weeks post-transplantation (Figure 2b ). In these animals, NAC administered i.p. induced within 1 week a significant drop in their white blood cell counts compared with the VEH-treated KI CT mice, more pronounced after 3 weeks. The i.p. injections of NAC also improved red blood cell and platelet counts in KI CT mice after 3 weeks. No significant differences in peripheral blood cell numbers were noted between the VEH and the NAC treatments of mice engrafted with only WT cells (WT CT ). These data suggested that the anti-oxidant NAC might target more specifically Jak2
V617F -expressing cells in vivo. After 3 weeks of i.p. treatment (14 weeks after transplantation) mice were killed and spleen were weighed (Figure 2c ). All VEHtreated KI CT mice had developed splenomegaly. In contrast, the spleens of NAC-treated KI CT animals presented a markedly reduced size, nearly to WT CT mouse value. Histological examination of the spleens revealed a typical spreading of the red pulp at the expense of the white pulp in the KI CT compared with WT CT mice ( Figure 2d ). NAC treatment of KI CT mouse model was accompanied with a visible restoration of spleen structure and lymphoid white pulp territories.
NAC specifically targets Jak2 V617F -positive KI cells
In mouse PV, the associated splenomegaly has been reportedly linked to an extramedullary hematopoiesis in the spleen, with prevalence of progenitors and erythroid lineage hyperplasia.
5,6,27
Thus, we assessed the effect of in vivo NAC treatment on the frequency of erythroid and myeloid progenitor cells in BM and spleen ( Figure 3 ). Cells were plated in methylcellulose in absence of added growth factors to identify spontaneous erythroid colonies (endogenous erythroid colony), a hallmark of PV. Two days later, BM-and spleen-derived EECs were detected only from KI CT mice and scored (Figure 3a) . Interestingly, NAC treatment had a tendency to decrease the frequency of EECs but the We determined the number of BFU-E and CFU-GM progenitors after 7 days of culture in methylcellulose in presence of growth factors ( Figure 3b ). As expected, Jak2
V617F induced the expansion Reactive oxygen species in Jak2 V617F -driven pathogenesis C Marty et al of hematopoietic progenitor cells. The differences between VEHtreated KI CT and WT CT mice were significant in the spleen but not in BM, as it was previously reported in constitutive KI mice. 6 After 3 weeks of NAC i.p., we observed a drop in the frequencies of BFU-E and CFU-GM colonies in KI CT mice compared with the VEH-treated group, without noticeable differences in control WT CT animals. Genotyping of BFU-E derived from KI CT mice showed that early erythroid progenitor compartment from Jak2 V617F KI origin raised from the initial 30% to 95% and 92% in BM and spleen, respectively, 14 weeks after transplantation (Figure 3c) . Thus, the Jak2 V617F KI clones out-competed the Jak2 WT cells. Remarkably, colony genotyping also revealed that NAC induced an increase in the frequency of Jak2
WT cells compared with heterozygous Jak2 V617F KI cells in BM and spleen (Figure 3c ). After NAC treatment, there were 45.7% and 66.9% of clones from KI origin remaining in BM and spleen of KI CT mice, respectively.
NAC decreases oxidative DNA damages and DSBs in KI mice
We examined the effect of NAC on ROS-mediated DNA damages by Dot Blot analysis of the 8-oxo-G (Figure 4a ). After 3 weeks of NAC i.p., the 8-oxo-G intensity in KI CT mouse BM was reduced compared with VEH-treated KI CT mice, whereas there was no observable change between the levels of 8-oxo-G detected in VEH-and NAC-treated WT CT animals ( Figure 4a ). As DSBs arise after replication of damaged DNA and NAC decreased the level of 8-oxo-G oxidative lesions in KI CT mice, we next examined the effect of NAC on accumulation of DSBs. High levels of DSBs in KI CT mice were monitored by the increase in g-H2AX foci in KI CT compared with WT CT mouse BM cells (Figure 4b) . Notably, in vivo NAC treatment significantly decreased the amount of g-H2AX foci in KI CT mice without affecting the basal level of DSBs in WT CT animals. Jak2 V617F has been suggested to promote homologous recombination in response to DSBs leading to loss of heterozygosity in MPN patients. [1] [2] [3] [4] 20 However, this phenomenon had yet to be reported in mouse models. As mentioned above, we performed PCR genotyping of early progenitors from 7-day methylcellulose cultures of BM and spleen cells from VEH-and NAC-treated transplanted KI CT mice. Electrophoresis of PCR products showed various proportions, depicted in Figure 3c , of the expected 2-band pattern corresponding to the heterozygous Jak2 WT /Jak2
V617F clones and a single band matching the Jak2 WT /Jak2
WT status when BFU-E colonies derived from VEH-and NAC-treated KI CT animals were analyzed (Figure 4c , 'Hetero. KI' and 'WT'). Unexpectedly, 12.5% and 16.7% BFU-E derived, respectively, from BM and spleen from one of the VEH-treated KI CT mice, presented a single band characteristic of a homozygous Jak2
V617F
/Jak2
V617F genotype (Figure 4c , 'Homo. KI'). We confirmed these results by sequencing genomic DNA extracted from several of these potential homozygous KI clones, using WT clones as controls (Figure 4d) . These results could indicate either a homologous recombination event in mouse resulting in the Jak2 V617F homozygosity or the deletion of the WT allele. A role for catalase in JAK2 V617F -mediated ROS accumulation in mouse and in human patients Cells respond to oxidative stress (above physiological ROS levels) through the induction of several signaling pathways, including PI3K/AKT that could participate in the development of MPNs. 28 AKT negatively regulates the Forkhead O transcription factor family that targets expression of a variety of anti-oxidant enzymes, including the glutathione peroxidases, catalase and superoxide dismutases. JAK2
V617F is known to induce constitutive activation of AKT in different systems, as observed in BM cells of KI origin (Figure 5a ). We tested mRNA expression levels of Sod1-3, Gpx1-8 and catalase in both the LSK and the Lin À cell compartments sorted from KI and WT mice. There was a significant decrease in catalase gene expression in Jak2 V617F KI cells compared with WT cells resulting in a decreased level of catalase protein (Figures 5b  and c) . Transcriptional patterns of the other tested genes were not as conclusive (data not shown) when matched to the expression profile in human CD34 þ samples. We used a murine Ba/F3 cell line expressing EPO-R together with either JAK2
WT or JAK2 V617F in order to test the effect of JAK2 and AKT inhibitors on catalase expression. First, we confirmed a marked accumulation of ROS in Ba/F3-EPO-R-JAK2
V617F cells compared with cells expressing endogenous level of Jak2 (control) or JAK2
WT (Figure 5d ). Chemical inhibition of the PI3K/AKT pathway with LY294002 or AKTi, and of JAK2 with AZD1480, restored catalase protein level in JAK2 V617F -positive cells to the levels found in control and JAK2
WT cell lines (Figure 5e ). These results suggest that JAK2 V617F -mediated decrease in catalase could be mediated through PI3K and AKT activation.
Human CD34 þ cells isolated from JAK2 V617F -positive PV and primary myelofibrosis patients were induced towards erythroid differentiation in presence of EPO, SCF and IL3 for 7 days. Cells presented a significant increase in ROS accumulation compared with control patients (Figure 5f ). Concomitantly, gene expression of catalase decreased in MPNs compared with normal CD34 þ cells (Figure 5g ).
DISCUSSION
Taken together these data confirmed in mice and patients that JAK2
V617F induces accumulation of ROS 19, 29, 30 and showed an increase in oxidation of DNA and DSBs. Interestingly, DNA damage-induced apoptosis could be avoided thus contributing to genetic instability, by decreasing p53 activity and subsequent checkpoints, 31 inhibiting Bcl-xL deamidation, 32 and phosphorylating histone H3 tyrosine 41 residue (H3Y41), which excludes heterochromatin protein 1a (HP1a) and promotes expression of oncogenes such as LMO2. 33, 34 Thus, in our system, the increase in ROS mediated by JAK2 V617F has the potential to cause additional mutations that could contribute to disease progression.
Anti-oxidant NAC treatment induced the reduction in both the 8-oxo-G and DSB levels in KI mice. Moreover, in the NAC-treated KI mice we observed a collapse in the early progenitor (BFU-E and CFU-GM) numbers linked to a specific reduction in the Jak2 V617F -positive clones. This result suggests two mechanisms for NAC action ( Figure 6 ): (i) the elimination of the Jak2 V617F -positive cells through death mechanisms or (ii) the inhibition of the proliferative advantage of Jak2 V617F -positive KI mouse cells over Jak2 WT cells. Jak2 V617F -dependent ROS accumulation may be responsible for clonal dominance and expansion of mutated cells and thus the progression of the disease through an increase in DNA damages. ROS elevation has been shown to decrease HSC self-renewal capacities but to drive HSC out of quiescence. 23, 35 Similar mechanisms could be involved in KI mice. It is expected that NAC may inhibit ROS production activated by PI3K/AKT. In addition, we found that NAC slightly inhibits EPO-induced JAK2/ signal transducers and activators of transcription signaling pathway (data not shown) suggesting a possible role in restoring phosphatase activities. 36 Alternatively, environmental cells such as megakaryocytes, granulocytes and stromal cells could contribute to ROS elevation either directly or by the release of proinflammatory cytokines. In accordance to this hypothesis, the level of pro-inflammatory cytokines are high in MPN patients 37 and may WT or JAK2 V617F were measured using DHE labeling. (e) The three Ba/F3 cell lines were treated or not with LY294002 or AKTi overnight and AZD1480 for 6 h. Catalase levels were studied by western blotting. Actin serves as loading control. (f) CD34 þ cells isolated from control (n ¼ 5) and JAK2
V617F
-positive MPN (n ¼ 9) patients were cultured for 7 days in erythroid differentiation conditions. ROS levels were detected by DHE labeling. (g) Taqman was conducted to detect catalase mRNA in CD34 þ cells (controls, n ¼ 14 and MPNs, n ¼ 7). 2-microglobin (B2M) serves as housekeeping gene. *Po0.05.
have a role both in JAK2 V617F clonal dominance, as described for TNF alpha, 38 and in the spleen size as suggested by the effects of JAK2 inhibitors in patients. 39 Altogether, these mechanisms could explain the rapid and potent effect of NAC in KI mice. Future studies should include a long-term monitoring to explore whether NAC treatment can prevent the emergence of a PV-like phenotype when early administered and delay the evolution into myelofibrosis when administered later. Yet, the degree of contribution between orally delivered NAC and the i.p. route is not clear and should be re-evaluated. As numerous hematological malignancies including chronic myeloid leukemia, acute myeloid leukemias and myelodysplastic syndromes, display high levels of ROS, it would be interesting to test the efficiency of anti-oxidant molecules alone or in combination with chemotherapeutics agents. 40 Our study suggests that a decrease of the detoxifying enzyme catalase in both KI mice and JAK2 V617F -positive MPNs is part of the mechanism resulting in JAK2 V617F -induced ROS elevation. Thus, constitutive activation of the PI3K/AKT signaling axis by JAK2 V617F may inhibit Forkhead O activity accounting for the decrease in catalase expression and ROS accumulation. In good agreement with this, previous work has shown that loss of Forkhead O3 in knockout mice causes increased ROS accumulation and leads to myeloproliferative syndrome. 28 In a chronic myeloid leukemia mouse model, it has been shown that HSCs initiating the disease are spared from the accumulation of ROS, which could have detrimental effects on their stem cell properties because AKT activation and subsequently Forkhead O 3a nuclear localization are regulated by TGF b. 41 It will be interesting to investigate if such a mechanism may operate in JAK2 V617F -positive HSCs. In addition, it would be worth testing whether dietary factors such as selenium, iron, zinc, copper and manganese that are necessary for anti-oxidant enzyme activity, would improve the symptoms of Jak2 V617F KI mice. The present study could not definitively eliminate the impact of JAK2 V617F activity on the formation, as opposed to the detoxification, of ROS by a NADPH oxidase as previously described in cell lines 30 and through the activation of Rac2 GTPase. 29 Indeed, Rac2 GTPase alters mitochondrial membrane potential and electron flow through the mitochondrial respiratory chain complex III, thereby generating high levels of ROS in chronic myeloid leukemia and PV patients.
This study suggests that anti-oxidative drugs, lowering ROS levels, deserve to be tested alone or in combination with other compounds such as the currently developed JAK2 inhibitors to block or delay progression of MPN. These drugs would probably act by inhibiting the JAK2 V617F -mediated clonal dominance and DNA damages. V617F -positive cells may increase as a result of: (i) JAK2 V617F -mediated decrease in the detoxifying enzyme catalase via activation of the PI3K/AKT pathway; (ii) the release of pro-inflammatory cytokines (such as TNF alpha, TGF beta, interleukins) from environmental cells including granulocytes, megakaryocytes (MKs) and stromal cells; and (iii) a direct release from MKs and granulocytes. In turn, ROS augmentation might inhibit phosphatase activities leading to a prolonged phosphorylation-dependent JAK/STAT signaling. NAC is expected to display a broad reduction of ROS levels rising from all these sources that would contribute to a decrease in both cell proliferation and DNA damage resulting in blocking disease progression.
